Amneal Pharmaceuticals shorts hit a one-year high as analysts turn more positive

Amneal Pharmaceuticals dropped 5.7% over the past week to close at $20.21, while the median of its closest peers gained 0.8%. The stock is now almost exactly where it started the year, and short sellers have been adding positions at the fastest rate in at least twelve months.

Short interest in Amneal has climbed 22% over the past month to reach 4.6% of free float, the highest reading in the data for at least a year. The move is not evenly distributed across time: shorts were largely flat through September, then jumped sharply in the week of October 23, adding roughly 2.7 million shares in a single week before stabilising. Despite that increase in borrowed shares, the lending market remains wide open. Availability, the ratio of shares still available to borrow versus shares already out on loan, is running at 2,767%, meaning lenders have far more supply than shorts have demand. Borrowing costs confirm the same picture: the cost to borrow is 0.54% annually, elevated 17% from a week ago but still near its lowest level of the year. The borrow market is not signalling any squeeze pressure. Options positioning has drifted more cautious too. The put/call ratio is 0.73, running about 1.4 standard deviations above its 20-day average of 0.58, though the year's range (from 0.0018 to 6.21) puts the current reading firmly in neutral territory.

The Street is pulling in the opposite direction from the shorts. JP Morgan raised its price target on Amneal to $25 this week, the second consecutive raise from the same analyst in two weeks, up from $22 at reinstatement in late August. Oppenheimer started coverage in September at Outperform with a $27 target, and Leerink Partners also initiated at Outperform. Barclays and UBS have both lifted targets in recent months. The consensus sits at $23.43, implying roughly 16% upside from current levels, and all named firms that have opined recently are at Overweight or Outperform. The valuation picture supports some of that optimism: Amneal trades at 17.1 times trailing earnings with an EV/EBITDA of 10.4 times, a multiple that has compressed slightly over the past month. The earnings yield factor scores in the 87th percentile of the ORTEX universe, a signal that the stock looks cheap relative to its earnings power. Where the Street is more cautious is EPS surprise, which ranks in just the 7th percentile, meaning the company has a recent habit of missing estimates.

Amneal's own Medicaid reimbursement data, published by the Centers for Medicare and Medicaid Services, adds a note of caution. CMS figures show that Medicaid dollars reimbursed to Amneal have fallen for four consecutive quarters, reaching $102.8 million in the period ending January 2026. Medicaid prescription volumes have followed the same path, also declining for four consecutive quarters, with 3.36 million prescriptions in the latest period. Neither dataset has been shown to lead the company's reported financials, so the streak cannot be read as predictive. But the persistent decline is consistent with the competitive pressures in generic drug pricing that have weighed on the whole sector.

The ownership picture at Amneal is unusual and worth understanding. Four members of the Patel family, Tushar, Chintu, Chirag and Dipan, collectively control well over 35% of shares outstanding and all carry Schedule 13D activist filings on EDGAR. These are insider-owners, not external activists, but the 13D designation is significant: it signals they hold shares with intent beyond passive investment. Tushar Patel is the largest individual holder at 17.6% of shares, and his stake grew materially in the August filing versus the prior disclosure. Chintu Patel's last filing showed a stake increase to 9.4% from 8.2%, while Chirag Patel moved from 7.1% to 8.4%. Dipan Patel's stake has moved in the opposite direction, falling to 5.4% from 7.6% per the most recent filing from March 2026. BlackRock holds 7.6% as a passive institutional holder. These are as-last-disclosed positions; holders below 5% are not required to file again. Away from the founding family, insider transaction data through September shows net selling over the prior 90 days of roughly 413,000 shares valued at around $7.2 million, concentrated in open-market sales by the Chief Legal Officer and two executive vice presidents in August.

The next scheduled earnings print is in early March 2027. Amneal's most recent earnings-day reaction on record was a 4.3% fall on October 30, 2026, following the Q3 report. What to watch between now and March is whether short interest continues its upward march, whether the gap between a bullish analyst consensus and a rising short base narrows or widens, and whether the Medicaid reimbursement decline starts to show up in the company's own reported revenue line.